Pfizer Will Not Launch EU Adalimumab
Despite Expected Imminent Approval For Amsparity Biosimilar To Humira
Executive Summary
Pfizer has announced that it does not plan to market its Amsparity adalimumab biosimilar in Europe despite it having been endorsed by the EMA in December and being in line for an imminent approval from the European Commission.
You may also be interested in...
Organon Foresees US Adalimumab Discounts Hitting 80%-90%
Organon CEO Kevin Ali has suggested that discounts for US Humira biosimilars could “range anywhere between 80% and 90%” by 2025-2026, amid a slew of competition on adalimumab starting within weeks.
Humira In 2023: The $17bn Biosimilar Opportunity
The advent of US biosimilar competition to Humira in 2023 represents the largest ever loss-of-exclusivity opportunity for the off-patent industry, with the first adalimumab rival expected to hit the US market at the end of this month. But with a host of other biosimilars expected to launch throughout the year, how will competition play out in the long term?
Humira Biosimilars Prepare For US Competition In 2023
The advent of biosimilar competition to Humira in the US in 2023 represents the largest loss-of-exclusivity opportunity ever for the off-patent industry. But with a host of biosimilar sponsors awaiting launches throughout the year, it remains to be seen how competition will play out.